Drug Trial Radar · NCT06635785
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
387
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
AI-081Drug
AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: 21 Days
- Dose Limiting Toxicity (DLT)Time frame: 21 Days
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
University of Florida UF Health Cancer Center
Gainesville, Florida · Recruiting
Memorial Healthcare System
Hollywood, Florida · Recruiting
Ocala Oncology Center PL DBA Florida Cancer Affiliates
Ocala, Florida · Recruiting
AdventHealth Cancer Institute
Orlando, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Norton Cancer Center
Louisville, Kentucky · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
The Tisch Cancer Institute, Mount Sinai Medical Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill Cancer Center
Chapel Hill, North Carolina · Recruiting
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina · Recruiting
Novant Health Cancer Institute
Winston-Salem, North Carolina · Recruiting
The Ohio State University James Cancer Center
Columbus, Ohio · Recruiting
Prisma Health
Greenville, South Carolina · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Texas Health San Antonio Mays Cancer Center
San Antonio, Texas · Recruiting
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.